Lixin Biotech

Lixin Biotech is a clinical-stage biopharmaceutical company based in Hangzhou, China, focused on the discovery and development of innovative biotherapeutics for the treatment of cancer. The company utilizes a proprietary protein engineering platform to design multi-functional molecules, including bispecific antibodies and fusion proteins, that can simultaneously modulate multiple signaling pathways within the tumor microenvironment. Its lead asset, LX001, is a bifunctional fusion protein targeting both PD-L1 and TGF-beta, currently in Phase 2 clinical trials for various refractory solid tumors. Lixin Biotech aims to provide more effective therapeutic options for patients who do not respond to existing checkpoint inhibitors by addressing complex mechanisms of immune evasion.